# US 2024/0374791 A1 · Porous hydrophilic composites for use in promoting bone growth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0374791 A1
- Document ID: US20240374791A1
- Status: Published application
- Kind: A1
- Application number: 18/292,355
- Filed: 2022-07-29
- Published: 2024-11-14
- Earliest claimed: 2021-07-30
- Assignees: Promimic AB
- Applicants: Promimic AB
- Inventors: Per Kjellin; Line Vikingsson; Hoda Fathali; Gunnar Simonarson; Oscar Davidsson
- Web page: https://patentgrep.com/patent/US20240374791A1

## CPC

- A61L 27/46: with phosphorus-containing inorganic fillers
- A61L 27/06: Titanium or titanium alloys
- A61L 27/28: Materials for coating prostheses
- A61L 27/34: Macromolecular materials
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- A61L 31/022: {Metals or alloys}
- A61L 31/10: Macromolecular materials
- A61L 31/127: {containing fillers of phosphorus-containing inorganic materials}
- A61L 31/146: {Porous materials, e.g. foams or sponges}
- C01B 25/32: Phosphates of magnesium, calcium, strontium, or barium
- C01B 25/327: {After-treatment}
- A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 40/00: Manufacture or treatment of nanostructures
- C01P 2002/02: Amorphous compounds
- C01P 2002/72: by d-values or two theta-values, e.g. as X-ray diagram
- C01P 2004/64: Nanometer sized, i.e. from 1-100 nanometer
- C01P 2006/12: Surface area
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C01P: INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS

## Abstract

Porous hydrophilic composites for use in promoting bone growth are disclosed, along with methods for their preparation. The composites comprise a porous biodegradable polymer matrix, and nanosized calcium phosphate (CaP) homogeneously dispersed throughout the polymer matrix. The CaP has a specific surface area in the range of about 180 to about 380 m2/g.

## Claims

### Claim 1

A porous hydrophilic composite for promoting bone growth, the composite comprising:
(a) a porous biodegradable polymer matrix, and
(b) nanosized calcium phosphate (CaP) homogeneously dispersed throughout the polymer matrix, wherein the CaP has a specific surface area in the range of about 180 to about 380 m2/g;
with the proviso that the composite does not contain any copolymer(s) of lactic acid and glycolic acid

### Claim 2 (depends on 1)

The porous hydrophilic composite of claim 1, wherein the nanosized CaP is amorphous calcium phosphate (ACP), beta-TCP, calcium deficient HA (CDHA) or hydroxyapatite (HA)

### Claim 3 (depends on 1)

The porous hydrophilic composite of claim 1, wherein the CaP is nanocrystalline.

### Claim 4 (depends on 1, 2)

The porous hydrophilic composite of claim 1 or claim 2, wherein the CaP is amorphous.

### Claim 5

The porous hydrophilic composite of any preceding claim, wherein the CaP has a specific surface area in the range of about 200 to about 350 m2/g.

### Claim 6

The porous hydrophilic composite of any preceding claim, wherein the polymer matrix comprises or consists of poly(caprolactone) (PCL), poly(lactic acid) (PLA), poly(glycolic acid) (PGL), poly(vinyl alcohol) (PVA), soluble collagen, hyaluronic acid, glycerine or chitosan.

### Claim 7

The porous hydrophilic composite of any preceding claim, wherein the polymer matrix comprises or consists of poly(caprolactone) (PCL).

### Claim 8

The porous hydrophilic composite of any preceding claim, wherein the ratio of CaP to polymer matrix is about 1:4 to about 3:1 by weight.

### Claim 9

The porous hydrophilic composite of any preceding claim which has a specific surface area in the range of about 5 to about 50 m2/g.

### Claim 10

The porous hydrophilic composite of any preceding claim further comprising from about 0.5 to 50 wt % of a biocompatible organic polyol, based on the total weight of the composite including the biocompatible organic polyol.

### Claim 11 (depends on 10)

The porous hydrophilic composite of claim 10, wherein the organic polyol is adsorbed on at least a portion of an internal and/or external surface thereof and/or forms a coating on at least a portion of an internal and/or external surface thereof.

### Claim 12 (depends on 10, 11)

The porous hydrophilic composite of claim 10 or claim 11, wherein the organic polyol is glycerol, propylene glycol, polyvinyl alcohol or a polyethylene glycol with a molecular weight in the range of about 200 to about 2,000.

### Claim 13 (depends on 10, 11, 12)

The porous hydrophilic composite of any of claims 10 to 12 wherein the organic polyol is glycerol.

### Claim 14

A scaffold for use in bone reconstruction, the scaffold comprising a substrate and the porous hydrophilic composite of any preceding claim.

### Claim 15 (depends on 14)

The scaffold of claim 14, wherein the substrate is selected from orthopaedic and dental implants.

### Claim 16 (depends on 15)

The scaffold of claim 15, wherein the substrate is selected from screws, spinal fusion cages, wires, meshes, nails, pins, rods, plates, hip stems, ostomy bag ports, bone anchored hearing aids, and dental implant abutments.

### Claim 17 (depends on 14, 15, 16)

The scaffold of any of claims 14 to 16, wherein the substrate is made from metal, ceramic, graphitic material or a polymer.

### Claim 18 (depends on 14, 15, 16, 17)

The scaffold of any of claims 14 to 17, wherein the substrate is made from titanium and its alloys, stainless steel, zirconia, alumina toughened zirconia, pyrocarbon, or PEEK, preferably titanium or PEEK.

### Claim 19

A process for the preparation of a porous hydrophilic composite for promoting bone growth, the process comprising:
(a) mixing a solution of a biodegradable polymer in a first solvent with nanosized calcium phosphate (CaP), preferably with a dispersion of nanosized calcium phosphate (CaP) in a second solvent, until the CaP is homogeneously distributed throughout the resulting mixture;
(b) solidifying the mixture of step (a) to form a gel; and
(c) removing the first and second solvents from the gel of step (b) by washing with a third solvent to leave a porous hydrophilic composite containing the nanosized CaP homogeneously dispersed in a porous polymer matrix.

### Claim 20 (depends on 19)

The process of claim 19, wherein the third solvent is IPA or water, preferably water.

### Claim 21

A process for the preparation of a hydrophilic composite for promoting bone growth, the process comprising:
(a1) mixing a solution of a biodegradable polymer in a first solvent with nanosized calcium phosphate (CaP), preferably with a dispersion of nanosized calcium phosphate (CaP) in a second solvent, until the CaP is homogeneously distributed throughout the resulting mixture;
(b1) solidifying the mixture of step (a) on a substrate to form a gel; and
(c1) removing the first and second solvents from the gel of step (b) by evaporation to leave a layer of a porous hydrophilic composite containing the nanosized CaP dispersed throughout a polymer matrix on the surface.

### Claim 22 (depends on 19, 20, 21)

The process of any of claims 19 to 21, wherein the first and second solvents are the same.

### Claim 23 (depends on 19, 20, 21, 22)

The process of any of claims 19 to 22, wherein the first and second solvents are independently selected from THE, dioxane and acetone, preferably wherein the first and second solvents are both acetone.

### Claim 24 (depends on 19, 20, 21, 22, 23)

The process of any of claims 19 to 23, wherein the nanosized CaP is amorphous calcium phosphate (ACP), beta-TCP, calcium deficient HA (CDHA) or hydroxyapatite (HA)

### Claim 25 (depends on 19, 20, 21, 22, 23, 24)

The process of any of claims 19 to 24, wherein the polymer matrix comprises or consists of poly(caprolactone) (PCL), poly(lactic acid) (PLA), poly(glycolic acid) (PGL), poly(vinyl alcohol) (PVA), collagen, hyaluronic acid, chitin or chitosan, preferably wherein the polymer matrix comprises or consists of poly(caprolactone) (PCL).

### Claim 26 (depends on 19, 20, 21, 22, 23, 24, 25)

The process of any of claims 19 to 25, wherein the process further comprises:
(d) immersing the porous hydrophilic composite in a solution comprising a biocompatible organic polyol;
(e) removing the porous hydrophilic composite from the solution; and
(f) drying the porous hydrophilic composite.

### Claim 27 (depends on 26)

The process of claim 26, wherein the organic polyol is glycerol, propylene glycol, polyvinyl alcohol or a polyethylene glycol with a molecular weight in the range of about 200 to about 2,000.

### Claim 28 (depends on 26)

The process of claim 26, wherein the organic polyol is glycerol.

### Claim 29 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The process of any of claims 19 to 28, wherein the CaP has a specific surface area in the range of about 180 to about 380 m2/g.

### Claim 30 (depends on 29)

The process of claim 29, wherein the CaP has a specific surface area in the range of about 200 to about 350 m2/g.

### Claim 31

A method for the preparation of nanosized CaP, the method comprising mixing a dispersion of a non-phosphate calcium salt in a suitable non-aqueous solvent with an aqueous phosphoric acid solution to form amorphous nanosized CaP, and optionally contacting the amorphous CaP with water to convert it to an alternative form of CaP.

### Claim 32 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A product obtainable by the process of any of claims 19 to 31.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 32)

An injectable formulation comprising a dispersion of particles of the porous hydrophilic composite of any of claim 1 to 13 or 32 and a pharmaceutically acceptable solvent.

### Claim 34 (depends on 33)

The injectable formulation of claim 33, wherein the pharmaceutically acceptable solvent is selected from glycerol, water for injection, propylene glycol and PEG-12.
